within Pharmacolibrary.Drugs.ATC.N;

model N06AX06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 209 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,
    adminCount     = 1,
    Vd             = 0.352,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009000000000000001,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Nefazodone is an atypical antidepressant previously used for the treatment of major depressive disorder and, less frequently, anxiety disorders. It acts primarily by inhibiting the reuptake of serotonin and norepinephrine and antagonizing 5-HT2 receptors. Due to rare cases of hepatotoxicity, nefazodone has been withdrawn from several markets, including the US and parts of Europe, though it is still available in some countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following a single oral dose of 200 mg in healthy adult volunteers. Both sexes included, ages ranged from 18-50 years.</p><h4>References</h4><ol><li><p>Greene, DS, &amp; Barbhaiya, RH (1997). Clinical pharmacokinetics of nefazodone. <i>Clinical pharmacokinetics</i> 33(4) 260–275. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199733040-00002&quot;>10.2165/00003088-199733040-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9342502/&quot;>https://pubmed.ncbi.nlm.nih.gov/9342502</a></p></li><li><p>Kaul, S, et al., &amp; Barbhaiya, RH (1995). Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. <i>Journal of clinical pharmacology</i> 35(8) 830–839. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1995.tb04127.x&quot;>10.1002/j.1552-4604.1995.tb04127.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8522641/&quot;>https://pubmed.ncbi.nlm.nih.gov/8522641</a></p></li><li><p>Ferry, N, et al., &amp; Sassard, J (1994). Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. <i>Fundamental &amp; clinical pharmacology</i> 8(5) 463–473. DOI:<a href=&quot;https://doi.org/10.1111/j.1472-8206.1994.tb00827.x&quot;>10.1111/j.1472-8206.1994.tb00827.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7875642/&quot;>https://pubmed.ncbi.nlm.nih.gov/7875642</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06AX06;
